Kenya Class A Listing: Nine Dossier Items, PVoC and Fees
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
Content verified as of October 30, 2026
1. Key takeaways
- Class A in Kenya is a listing rather than a registration. Applications go through prims.pharmacyboardkenya.org and fees are charged upon submission.
- The dossier consists of nine items; the third item, the PVoC pre-export verification certificate, is issued jointly by a notified body and the Kenya Bureau of Standards (KEBS) and may be replaced by a Certificate of Conformity (CoC).
- Personal protective equipment (face masks, surgical masks, gloves) must additionally carry a Certificate of Analysis (CoA) issued by a PPB-recognized laboratory.
- This is the lowest fee tier: Class A registration for imported products is USD 100 (locally manufactured USD 50) and annual retention is USD 50.
- Listing does not mean exemption from review: PPB examines the dataset and may issue an input request. The review clock stops from the issuance of the input request until a complete and satisfactory response is received.
2. Legal basis
| Instrument | Reference number | Date issued or effective | Provision | Relevance to this article |
|---|---|---|---|---|
| Guidelines for Registration of Medical Devices including In-Vitro Diagnostics | HPT/PER/HTR/GUD/011, Rev.02 | Effective January 31, 2022; review due January 1, 2027 | Class A listing procedure and the nine-item dossier | Nature of listing, submission portal, immediate charging, input requests and the clock-stop mechanism |
| Pharmacy and Poisons (Registration of Health Products and Technologies) Rules, 2022 | Legal Notice No. 100 of 2022 | Made on June 8, 2022 | Second Schedule (Class A medical devices registration USD 100.00) | The statutory fee tier corresponding to listing |
| Standards Act | Cap. 496 | Currently in force | KEBS functions provisions | Legal basis for KEBS operation of the PVoC programme |
| Pharmacy and Poisons Act | Cap. 244, Laws of Kenya | Enacted 1957, as amended | Section 3B(2)(b) | Ensuring imported products meet prescribed quality, safety and efficacy standards |
| KEBS PVoC legal basis currently in force | Legal Notice No. 78 of 2020 | April 28, 2020 (amended by LN 212 of 2020 and LN 53 of 2021) | Full text | Current basis and amendment history of pre-export verification of conformity |
3. Expert insights
Insight 1: The lightest form of market entry is not a light dossier
Within the nine-item list, the items that actually form the bar are precisely the two most often treated as annexes: the QMS certificate and the information on the sterilization method and validation standard. There are five acceptable forms of QMS evidence, namely ISO 13485, a free sale certificate attesting conformity with the US QSR, Japanese MHLW Ordinance No. 169, a declaration of adequate QMS, and EU-UK-Ireland CE certificates. This shows that PPB still locks in quality system evidence at the lowest risk class. GRZAN’s observation: companies that read listing as filling in a form are usually corrected for the first time at item nine.
Insight 2: PVoC comes first, meaning the standards track precedes the regulatory track
Item three requires a PVoC pre-export verification certificate issued jointly by a notified body and KEBS, or a CoC in substitution. This document sits outside PPB’s jurisdiction, so the company must first complete its actions on the standards and customs track before the listing dossier can be completed. KEBS inspection timelines are: for sea cargo, physical inspection within 4 working days of receiving the complete application form; for air cargo, within 1 working day; the draft CoC or CoR must be confirmed within 48 hours, after which it is issued as drafted and KEBS will not amend it once issued. These three timelines determine the earliest possible submission date for the listing dossier and should be back-calculated when scheduling.
Insight 3: The proposed label means the actual artwork, not a text draft
Item two requires the proposed label, explicitly pointing to the actual artwork and the packaging material in contact with the product or the secondary packaging. Item four further requires the IFU, patient information leaflet and promotional materials, including brochures and catalogues. This means marketing collateral must be finalized at the submission stage, and brochures and catalogues fall within the scope of review. The common trap is filing with a generic label and swapping in the finished packaging before launch, which triggers input requests or even change notifications.
Insight 4: The clock-stop mechanism reveals who is holding up the timeline
PPB registers and lists only applications that meet requirements, and may issue input requests when examining the dataset; the clock stops from issuance of the input request until a complete and satisfactory response is received. The current guidelines do not state specific review days in text. The first edition of the submission guidelines expressed it as 90 calendar days, with a surcharge of one third of the application fee if the applicant fails to respond within 90 calendar days. As a practical estimate, GRZAN notes that those days belong to that edition of the guidelines, and project scheduling should follow the actual PRIMS clock and the latest PPB notices. The key move available to companies is to embed the response SLA into internal workflows, because during a stop the clock is in the applicant’s hands.
4. Practical recommendations
- Start PVoC and the CoC first. Complete pre-export verification of conformity before the PRIMS submission and back-calculate the schedule using the 4-working-day sea and 1-working-day air inspection timelines.
- Choose the strongest of the five QMS forms. Prefer the ISO 13485 certificate, which reviewers know best, and check that its validity covers the whole review period.
- Finalize label artwork in one pass. Freeze the artwork, secondary packaging, IFU and brochures at the same version for submission.
- Prepare the CoA separately for PPE. Face masks, surgical masks and gloves need a CoA from a PPB-recognized laboratory; supplier self-test reports will not substitute.
- Set up an input request response mechanism. Assign a named person to respond to PRIMS messages within 48 hours so internal handoffs do not consume the stopped clock.
- Schedule annual retention by calendar year. Retention should be handled within the 3 months before year end, the system opens 60 days before the annual fee falls due, and the fee is non-refundable.
5. Verification checklist
- □ Are all nine dossier items complete (authorization letter, label artwork, PVoC or CoC, IFU and promotional materials, CoA, PPE CoA, sterilization information, country-of-origin approval, QMS certificate)?
- □ Has the PVoC pre-export verification certificate or substitute CoC been obtained and is it valid?
- □ Is the label artwork the actual finished draft, and does it include secondary packaging?
- □ For PPE products, is the CoA issued by a PPB-recognized laboratory?
- □ Is the QMS evidence one of the five acceptable forms, and does its validity cover the review period?
- □ Does the budget include Class A registration at USD 100 and annual retention at USD 50?
- □ Is input request monitoring with an internal response deadline in place on PRIMS?
- □ Is annual retention scheduled on the rhythm of within 3 months before year end and the system opening 60 days ahead?
Regulatory information verified as of October 30, 2026.
Across African markets, the GRZAN regulatory team focuses on jurisdictions including Kenya, Nigeria, South Africa and Egypt, and operates a verification mechanism built on primary regulatory sources: every regulatory conclusion published externally rests solely on official gazettes, the original text of competent authority guidelines and public legal databases, each marked with its verification date. Any figure, timeline or amount that cannot be located in an official source is labeled as a practical estimate and never presented as an assumption.
GRZAN services cover market access strategy and risk classification assessment; preparation and review of registration dossiers in CSDT, STED and CTD formats; selection and management of Local Authorized Representatives (LAR); quality management system and GMP/GSDP compliance support; post-market vigilance, change management and recall response; import customs clearance and PVoC coordination; and regulatory intelligence subscription with corporate compliance record-keeping.
For a Kenya market access plan tailored to your specific product, contact the GRZAN regulatory team at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us